Registration Dossier

Administrative data

Description of key information

The tests of Acute oral toxicity and Acute dermal toxicity were performed according to the following methods: 
Method B.1 tris: Acute Oral Toxicity - Acute Toxic Class Method, Directive 2004/73/EC, published in O.J. L152, 2004.
Method B.3 Acute Toxicity (Dermal), Directive 92/69/EEC, published in OJ L 383A, 1992.
Both: GLP study

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion
Dose descriptor:
LD50
Value:
2 000 mg/kg bw

Acute toxicity: via inhalation route

Link to relevant study records
Reference
Endpoint:
acute toxicity: inhalation
Data waiving:
exposure considerations
Justification for data waiving:
the study does not need to be conducted because exposure of humans via inhalation is not likely taking into account the vapour pressure of the substance and/or the possibility of exposure to aerosols, particles or droplets of an inhalable size
Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via dermal route

Endpoint conclusion
Dose descriptor:
LD50
Value:
2 000 mg/kg bw

Additional information

Justification for classification or non-classification

From the results of both acute toxicity studies (oral and dermal) follows that the substance is not classified as hazard substance.

LD50 > 2000 mg/kg bw (oral)

LD50 > 2000 mg/kg bw (dermal)